Title of article :
Durable Clinical Benefit of Pertuzumab in a YoungPatient with BRCA2 Mutation and HER2-OverexpressingBreast Cancer Involving the Brain
Author/Authors :
Koumarianou, Anna Hematology-Oncology Unit - Fourth Department of Internal Medicine - National and Kapodistrian University of Athens - Attikon University Hospital - Rimini - Haidari - Athens, Greece , Kontopoulou, Christina Second Radiology Department - Attikon University Hospital - National and Kapodistrian University of Athens,Rimini - Athens, Greece , Kouloulias, Vassilis Radiotherapy Unit - Second Radiology Department - Attikon University Hospital - National and Kapodistrian University of Athens - Rimini - Athens, Greece , Tsionou, Christina Maternity-Health - Halandri - Athens, Greece
Abstract :
Patients with HER2-positive breast cancer and brain metastases have limited treatment options, and, as a result of their poorperformance status and worse prognosis, they are underrepresented in clinical trials. Not surprisingly, these patients may not be fitenough to receive any active treatment and are offered supportive therapy. BRCA2 mutations are reported to be rarely associatedwith HER2-overexpressing advanced breast cancer and even more rarely with brain metastases at diagnosis. We report on a BRCA2-positive breast cancer patient with metastatic disease in multiple sites, including the brain, and poor performance status whoexhibited an extraordinary clinical and imaging response to the novel anti-HER2 therapy pertuzumab after multiple lines of therapyincluding anti-HER2 targeting. To our knowledge, the clinicopathologic and therapeutic characteristics of this patient point to aunique case and an urgent need for further investigation of pertuzumab in patients with brain metastases
Keywords :
Durable Clinical Benefit , Pertuzumab , Young Patient , BRCA2 Mutation , HER2-Overexpressing Breast Cancer Involving , Brain
Journal title :
Case Reports in Oncological Medicine
